Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 1/2020

23.01.2020 | short review

Evidence-based follow-up in non-small cell lung cancer

verfasst von: MD, BA, FACS Stefan B. Watzka

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

Purpose

Structured follow-up is an integral part of efficient care in non-small cell lung cancer (NSCLC). However, since randomized prospective clinical trials giving clear indications for an optimal follow-up algorithm are still missing, it is necessary to seek currently available evidence to determine which follow-up strategy is advisable. For this purpose, a review of the current literature has been undertaken.

Results

There is controversy in the literature about intensity, duration and modalities of follow-up in NSCLC. While some propose a higher intensity routine follow-up during the first 4 years after treatment, followed by yearly visits up to 5 years after treatment, others prefer a high-intensity follow-up for only the first 2 years, and yearly visits thereafter life-long. Most papers insist on measuring efficiency of routine follow-up upon its impact on overall survival. Routine chest CT should be integral part of the follow-up, while PET or PET/CT only in selected situations. The 2017 European Society for Medical Oncology guidelines formulate a consensus between all these positions by recommending visits every 6 months for the first 2 years, followed by life-long yearly surveillance, while for selected high-risk patients more frequent visits should be offered.

Conclusion

Current evidence from the literature supports a more intense routine follow-up in NSCLC during the first 2 years after treatment, followed by less frequent regular visits life-long.
Literatur
1.
Zurück zum Zitat Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, Vansteenkiste J, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv1–iv21. CrossRef Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, Vansteenkiste J, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv1–iv21. CrossRef
2.
Zurück zum Zitat Mollberg NM, Ferguson MK. Postoperative surveillance for non-small cell lung cancer resected with curative intent: developing a patient-centered approach. Ann Thorac Surg. 2013;95(3):1112–21. CrossRef Mollberg NM, Ferguson MK. Postoperative surveillance for non-small cell lung cancer resected with curative intent: developing a patient-centered approach. Ann Thorac Surg. 2013;95(3):1112–21. CrossRef
3.
Zurück zum Zitat Shirvani SM, Jiang J, Chang JY, Welsh JW, Gomez DR, Swisher S, et al. Comparative effectiveness of 5 treatment strategies for early-stage non-small cell lung cancer in the elderly. Int J Radiat Oncol Biol Phys. 2012;84(5):1060–70. CrossRef Shirvani SM, Jiang J, Chang JY, Welsh JW, Gomez DR, Swisher S, et al. Comparative effectiveness of 5 treatment strategies for early-stage non-small cell lung cancer in the elderly. Int J Radiat Oncol Biol Phys. 2012;84(5):1060–70. CrossRef
4.
Zurück zum Zitat Bryant AK, Mundt RC, Sandhu AP, Urbanic JJ, Sharabi AB, Gupta S, et al. Stereotactic body radiation therapy versus surgery for early lung cancer among US veterans. Ann Thorac Surg. 2018;105(2):425–31. CrossRef Bryant AK, Mundt RC, Sandhu AP, Urbanic JJ, Sharabi AB, Gupta S, et al. Stereotactic body radiation therapy versus surgery for early lung cancer among US veterans. Ann Thorac Surg. 2018;105(2):425–31. CrossRef
6.
Zurück zum Zitat Wright G, Manser RL, Byrnes G, Hart D, Campbell DA. Surgery for non-small cell lung cancer: systematic review and meta-analysis of randomised controlled trials. Thorax. 2006;61(7):597–603. CrossRef Wright G, Manser RL, Byrnes G, Hart D, Campbell DA. Surgery for non-small cell lung cancer: systematic review and meta-analysis of randomised controlled trials. Thorax. 2006;61(7):597–603. CrossRef
7.
Zurück zum Zitat Veronesi G, Bottoni E, Finocchiaro G, Alloisio M. When is surgery indicated for small-cell lung cancer? Lung Cancer. 2015;90(3):582–9. CrossRef Veronesi G, Bottoni E, Finocchiaro G, Alloisio M. When is surgery indicated for small-cell lung cancer? Lung Cancer. 2015;90(3):582–9. CrossRef
8.
Zurück zum Zitat Hu Y, McMurry TL, Isbell JM, Stukenborg GJ, Kozower BD. Readmission after lung cancer resection is associated with a 6-fold increase in 90-day postoperative mortality. J Thorac Cardiovasc Surg. 2014;148(5):2261–2267e1. CrossRef Hu Y, McMurry TL, Isbell JM, Stukenborg GJ, Kozower BD. Readmission after lung cancer resection is associated with a 6-fold increase in 90-day postoperative mortality. J Thorac Cardiovasc Surg. 2014;148(5):2261–2267e1. CrossRef
9.
Zurück zum Zitat Lou F, Sima CS, Rusch VW, Jones DR, Huang J. Differences in patterns of recurrence in early-stage versus locally advanced non-small cell lung cancer. Ann Thorac Surg. 2014;98(5):1755–60. discussion 60–1. CrossRef Lou F, Sima CS, Rusch VW, Jones DR, Huang J. Differences in patterns of recurrence in early-stage versus locally advanced non-small cell lung cancer. Ann Thorac Surg. 2014;98(5):1755–60. discussion 60–1. CrossRef
10.
Zurück zum Zitat Kenzik KM, Ganz PA, Martin MY, Petersen L, Hays RD, Arora N, et al. How much do cancer-related symptoms contribute to health-related quality of life in lung and colorectal cancer patients? A report from the Cancer Care Outcomes Research and Surveillance (CanCORS) Consortium. Cancer. 2015;121(16):2831–9. CrossRef Kenzik KM, Ganz PA, Martin MY, Petersen L, Hays RD, Arora N, et al. How much do cancer-related symptoms contribute to health-related quality of life in lung and colorectal cancer patients? A report from the Cancer Care Outcomes Research and Surveillance (CanCORS) Consortium. Cancer. 2015;121(16):2831–9. CrossRef
11.
Zurück zum Zitat Voltolini L, Paladini P, Luzzi L, Ghiribelli C, Di Bisceglie M, Gotti G. Iterative surgical resections for local recurrent and second primary bronchogenic carcinoma. Eur J Cardio Thorac Surg. 2000;18(5):529–34. CrossRef Voltolini L, Paladini P, Luzzi L, Ghiribelli C, Di Bisceglie M, Gotti G. Iterative surgical resections for local recurrent and second primary bronchogenic carcinoma. Eur J Cardio Thorac Surg. 2000;18(5):529–34. CrossRef
12.
Zurück zum Zitat Hamaji M, Allen MS, Cassivi SD, Deschamps C, Nichols FC, Wigle DA, et al. Surgical treatment of metachronous second primary lung cancer after complete resection of non-small cell lung cancer. J Thorac Cardiovasc Surg. 2013;145(3):683–90. discussion 90–1. CrossRef Hamaji M, Allen MS, Cassivi SD, Deschamps C, Nichols FC, Wigle DA, et al. Surgical treatment of metachronous second primary lung cancer after complete resection of non-small cell lung cancer. J Thorac Cardiovasc Surg. 2013;145(3):683–90. discussion 90–1. CrossRef
13.
Zurück zum Zitat Lou F, Huang J, Sima CS, Dycoco J, Rusch V, Bach PB. Patterns of recurrence and second primary lung cancer in early-stage lung cancer survivors followed with routine computed tomography surveillance. J Thorac Cardiovasc Surg. 2013;145(1):75–81. discussion –2. CrossRef Lou F, Huang J, Sima CS, Dycoco J, Rusch V, Bach PB. Patterns of recurrence and second primary lung cancer in early-stage lung cancer survivors followed with routine computed tomography surveillance. J Thorac Cardiovasc Surg. 2013;145(1):75–81. discussion –2. CrossRef
14.
Zurück zum Zitat Demicheli R, Fornili M, Ambrogi F, Higgins K, Boyd JA, Biganzoli E, et al. Recurrence dynamics for non-small-cell lung cancer: effect of surgery on the development of metastases. J Thorac Oncol. 2012;7(4):723–30. CrossRef Demicheli R, Fornili M, Ambrogi F, Higgins K, Boyd JA, Biganzoli E, et al. Recurrence dynamics for non-small-cell lung cancer: effect of surgery on the development of metastases. J Thorac Oncol. 2012;7(4):723–30. CrossRef
15.
Zurück zum Zitat Zhang Y, Zheng D, Xie J, Li Y, Wang Y, Li C, et al. Development and validation of web-based nomograms to precisely predict conditional risk of site-specific recurrence for patients with completely resected non-small cell lung cancer: a multiinstitutional study. Chest. 2018;154(3):501–11. CrossRef Zhang Y, Zheng D, Xie J, Li Y, Wang Y, Li C, et al. Development and validation of web-based nomograms to precisely predict conditional risk of site-specific recurrence for patients with completely resected non-small cell lung cancer: a multiinstitutional study. Chest. 2018;154(3):501–11. CrossRef
16.
Zurück zum Zitat Subramanian M, Liu J, Greenberg C, Schumacher J, Chang GJ, McMurry TL, et al. Imaging surveillance for surgically resected stage I non-small cell lung cancer: is more always better? J Thorac Cardiovasc Surg. 2019;157(3):1205–1217.e2. CrossRef Subramanian M, Liu J, Greenberg C, Schumacher J, Chang GJ, McMurry TL, et al. Imaging surveillance for surgically resected stage I non-small cell lung cancer: is more always better? J Thorac Cardiovasc Surg. 2019;157(3):1205–1217.e2. CrossRef
17.
Zurück zum Zitat McMurry TL, Stukenborg GJ, Kessler LG, Colditz GA, Wong ML, Francescatti AB, et al. More frequent surveillance following lung cancer resection is not associated with improved survival: a nationally representative cohort study. Ann Surg. 2018;268(4):632–9. CrossRef McMurry TL, Stukenborg GJ, Kessler LG, Colditz GA, Wong ML, Francescatti AB, et al. More frequent surveillance following lung cancer resection is not associated with improved survival: a nationally representative cohort study. Ann Surg. 2018;268(4):632–9. CrossRef
18.
Zurück zum Zitat Johnson BE. Second lung cancers in patients after treatment for an initial lung cancer. J Natl Cancer Inst. 1998;90(18):1335–45. CrossRef Johnson BE. Second lung cancers in patients after treatment for an initial lung cancer. J Natl Cancer Inst. 1998;90(18):1335–45. CrossRef
19.
Zurück zum Zitat Matsumura Y, Yano M, Yoshida J, Koike T, Kameyama K, Shimamoto A, et al. Early and late recurrence after intentional limited resection for cT1aN0M0, non-small cell lung cancer: from a multi-institutional, retrospective analysis in Japan. Interact CardioVasc Thorac Surg. 2016;23(3):444–9. CrossRef Matsumura Y, Yano M, Yoshida J, Koike T, Kameyama K, Shimamoto A, et al. Early and late recurrence after intentional limited resection for cT1aN0M0, non-small cell lung cancer: from a multi-institutional, retrospective analysis in Japan. Interact CardioVasc Thorac Surg. 2016;23(3):444–9. CrossRef
20.
Zurück zum Zitat Korst RJ, Kansler AL, Port JL, Lee PC, Altorki NK. Accuracy of surveillance computed tomography in detecting recurrent or new primary lung cancer in patients with completely resected lung cancer. Ann Thorac Surg. 2006;82(3):1009–15. discussion 15. CrossRef Korst RJ, Kansler AL, Port JL, Lee PC, Altorki NK. Accuracy of surveillance computed tomography in detecting recurrent or new primary lung cancer in patients with completely resected lung cancer. Ann Thorac Surg. 2006;82(3):1009–15. discussion 15. CrossRef
21.
Zurück zum Zitat Crabtree TD, Puri V, Chen SB, Gierada DS, Bell JM, Broderick S, et al. Does the method of radiologic surveillance affect survival after resection of stage I non-small cell lung cancer? J Thorac Cardiovasc Surg. 2015;149(1):45–52, 53.e1‑3. CrossRef Crabtree TD, Puri V, Chen SB, Gierada DS, Bell JM, Broderick S, et al. Does the method of radiologic surveillance affect survival after resection of stage I non-small cell lung cancer? J Thorac Cardiovasc Surg. 2015;149(1):45–52, 53.e1‑3. CrossRef
22.
Zurück zum Zitat Backhus LM, Farjah F, Liang CK, He H, Varghese TK Jr., Au DH, et al. Imaging surveillance and survival for surgically resected non-small-cell lung cancer. J Surg Res. 2016;200(1):171–6. CrossRef Backhus LM, Farjah F, Liang CK, He H, Varghese TK Jr., Au DH, et al. Imaging surveillance and survival for surgically resected non-small-cell lung cancer. J Surg Res. 2016;200(1):171–6. CrossRef
23.
Zurück zum Zitat Hellwig D, Groschel A, Graeter TP, Hellwig AP, Nestle U, Schafers HJ, et al. Diagnostic performance and prognostic impact of FDG-PET in suspected recurrence of surgically treated non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2006;33(1):13–21. CrossRef Hellwig D, Groschel A, Graeter TP, Hellwig AP, Nestle U, Schafers HJ, et al. Diagnostic performance and prognostic impact of FDG-PET in suspected recurrence of surgically treated non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2006;33(1):13–21. CrossRef
24.
Zurück zum Zitat Kanzaki R, Higashiyama M, Maeda J, Okami J, Hosoki T, Hasegawa Y, et al. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients. Interact CardioVasc Thorac Surg. 2010;10(6):1009–14. CrossRef Kanzaki R, Higashiyama M, Maeda J, Okami J, Hosoki T, Hasegawa Y, et al. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients. Interact CardioVasc Thorac Surg. 2010;10(6):1009–14. CrossRef
25.
Zurück zum Zitat Choi SH, Kim YT, Kim SK, Kang KW, Goo JM, Kang CH, et al. Positron emission tomography-computed tomography for postoperative surveillance in non-small cell lung cancer. Ann Thorac Surg. 2011;92(5):1826–32. discussion 32. CrossRef Choi SH, Kim YT, Kim SK, Kang KW, Goo JM, Kang CH, et al. Positron emission tomography-computed tomography for postoperative surveillance in non-small cell lung cancer. Ann Thorac Surg. 2011;92(5):1826–32. discussion 32. CrossRef
Metadaten
Titel
Evidence-based follow-up in non-small cell lung cancer
verfasst von
MD, BA, FACS Stefan B. Watzka
Publikationsdatum
23.01.2020
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 1/2020
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-019-00566-z